Heparin sodium Rx
Generic Name and Formulations:
Heparin sodium 1000, 5000, 10000units; per mL; IV or SC inj; preservative-free or preserved with benzyl alcohol.
Various generic manufacturers
Indications for Heparin sodium:
Adults and Children:
See full labeling. Individualize based on lab results and disease.
History of heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis (HITT). Hypersensitivity to pork products. When blood coagulation testing is not feasible. Uncontrolled active bleeding state, except when due to disseminated intravascular coagulation.
IM use not recommended. Confirm choice of correct strength prior to administration. Monitor for any degree of thrombocytopenia; discontinue if platelet count falls <100000/mm3 or if recurrent thrombosis develops; evaluate for HIT and HITT; if needed, give alternative anticoagulant. Major bleeding or conditions with increased risk of hemorrhage (eg, bacterial endocarditis, severe hypertension, surgery, hemophilia, hereditary antithrombin III deficiency receiving concurrent antithrombin III therapy, ulcerative lesions, continuous GI tube drainage, menstruation, liver disease with impaired hemostasis). Monitor blood coagulation tests (discontinue if test is unduly prolonged or if hemorrhage occurs), platelets, hematocrit during therapy. Heparin resistance (monitor). History of allergy. Not interchangeable (unit-for-unit) with low molecular weight heparins. Women >60yrs of age. Elderly. Neonates/infants (gasping syndrome due to benzyl alcohol), pregnancy, nursing mothers: use preservative-free formulations.
Potentiated by anticoagulants (eg, dicumerol, warfarin), antiplatelets (eg, salicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, celecoxib, thienopyridines, dipyridamole, hydroxychloroquine, glycoprotein IIb/IIIa antagonists including abciximab, eptifibatide, tirofiban) and others; caution. Antagonized by digitalis, tetracyclines, nicotine, antihistamines, IV nitroglycerin. Potentiated by concurrent treatment with antithrombin III (human) in patients with hereditary antithrombin III deficiency; reduce heparin dose.
Hemorrhage, thrombocytopenia, HIT and HITT, inj site irritation, hypersensitivity reactions, increased aminotransferase levels.
Formerly known under the brand names Panheparin, Lipo-Hepin, Liquaemin.
Sign Up for Free e-newsletters
- Choice of Breast Reconstruction After Mastectomy Affects Satisfaction, Quality of Life
- Bariatric Surgery Reduced Risk of Some Cancers in Obese Patients
- Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma
- The Caregivers' Cancer Journey
- Genetic Link Between Depression and Breast Cancer Remains Unclear
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Fertility Preservation in Hodgkin's Lymphoma Patients That Undergo Targeted Molecular Therapies: An Important Step Forward From the Chemotherapy Era
- Survey of ACEP Councilors Reveals NP, PA Staffing Models, Practice Patterns Vary
- Breath Analysis May Be an Effective Diagnostic for Pancreatic Cancer
- Genetic Susceptibility to Pancreatic Cancer Linked to 6 Specific Gene Mutations
- Dinner Hour and Sleep Habits Affect Risk of Breast, Prostate Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|